Donation of LUCEMYRA Available
CHCANYS, in partnership with Healthcare Ready is helping coordinate a donation offered by US WorldMeds, shared via FEMA HQ.
The donation is for LUCEMYRA, a drug used to mitigate opiate withdrawal symptoms for abrupt opiate discontinuation in adults. Given the existing opioid epidemic, this could be extremely useful in mitigating developing dependence for patients receiving invasive treatment for COVID-19.
Contact CHCANYS EM Team if you are interested.
Pure donation: 500 bottles of 96 tablets with an option for more if this can and will be used. Can provide more on request.
Overview: Medicine is used overseas & brought to the US. Non-addictive, non-opioid, indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, and FDA approved. Donor has been in conversation with the Pres of CHEST/ACCP and VA Nat Pulmonary & Critical Care Director.
COVID patients can show signs of opioid dependence due to being on mechanical ventilators in ICUs for up to 4 weeks with IV opioid for pain/sedation. Used for no more than 2 weeks to mitigate symptoms of opioid withdrawal to facilitate abrupt opioid discontinuation.
This medicine is used for patients who are presenting symptoms of Opioid withdrawal upon discontinuation of opioid therapy. Can be used when patient presents physical dependence/opioid withdrawal symptoms (OWS) after cessation of opioid therapy (post-trauma, post-injury), in surgery patient who abuses opioid therapy & requires detox because of OWS, in obstetrics/delivery patient who abuses opioid therapy & requires detox because of OWS, as a bridge for OUD patient about to be RX’ed MAT (i.e. Vivitrol®/naltrexone, etc.) & requires prior detox, as a bridge for the OUD patient who wishes to discontinue MAT therapy.
Should COVID-19 patients present opioid withdrawal symptoms after weeks of mechanical ventilation & IV opioid therapy, this drug could be used to mitigate opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. New ASAM (American Society of Addiction Management) Guide recommends as preferred outpatient treatment for opioid withdrawal symptoms
Location of Supply: ICS Connect - Infirst Healthcare, 420 International Blvd., Shepherdsville, KY 40165
Expiration: 11 Months from April 23rd, 2020 (expiration March 23rd, 2021)
Transportation: Donor will ship with tracking # through UPS
LUCEMYRA® (lofexidine) - approved prescribing information